title: A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer.
abstract: A phase I study of fixed-dose 5-fluorouracil (FU) and leucovorin (LCV), with excalating doses of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, was conducted in 16 patients with advanced colorectal adenocarcinoma. At doses typically used to treat arthritis patients (100-200 mg po BID), celecoxib did not increase toxicities expected from the chemotherapy alone. 5-FU and leucovorin did not affect COX-2 inhibition by celecoxib. Preliminary data suggest it is safe to combine celecoxib with standard chemotherapeutic agents, in treatment of patients with colorectal cancer.
authors.affiliation: Oregon Health and Science University Cancer Institute, Portland, OR, USA. blankec@ohsu.edu
authors.forename: Charles D
authors.initials: CD
authors.lastname: Blanke
authors.forename: Nora C
authors.initials: NC
authors.lastname: Mattek
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Deloughery
authors.forename: Dennis R
authors.initials: DR
authors.lastname: Koop
mesh_terms: D015746:Abdominal Pain; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000633:toxicity*; D000068579:Celecoxib; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage; D003967:Diarrhea; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D011720:Pyrazoles / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage
chemical_list: D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib; D002955:Leucovorin; D005472:Fluorouracil